Raymond James & Associates grew its position in Iqvia Holdings Inc (NYSE:IQV) by 13.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 557,127 shares of the medical research company’s stock after purchasing an additional 65,612 shares during the quarter. Raymond James & Associates’ holdings in Iqvia were worth $80,143,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of IQV. C J Advisory Inc bought a new stake in shares of Iqvia in the first quarter valued at approximately $27,000. Baystate Wealth Management LLC bought a new stake in Iqvia during the first quarter worth $27,000. Parkside Financial Bank & Trust lifted its stake in Iqvia by 140.2% during the first quarter. Parkside Financial Bank & Trust now owns 209 shares of the medical research company’s stock worth $30,000 after purchasing an additional 122 shares during the last quarter. Berman Capital Advisors LLC bought a new stake in Iqvia during the fourth quarter worth $46,000. Finally, ERTS Wealth Advisors LLC bought a new stake in Iqvia during the fourth quarter worth $46,000. 91.47% of the stock is currently owned by institutional investors.
Shares of IQV traded up $1.53 during trading hours on Wednesday, reaching $136.08. The stock had a trading volume of 7,595 shares, compared to its average volume of 1,248,719. Iqvia Holdings Inc has a 12 month low of $91.57 and a 12 month high of $146.10. The stock has a market capitalization of $26.09 billion, a price-to-earnings ratio of 26.58, a PEG ratio of 1.61 and a beta of 0.80. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.14 and a current ratio of 1.14.
Iqvia (NYSE:IQV) last posted its quarterly earnings data on Wednesday, May 1st. The medical research company reported $1.53 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.41 by $0.12. The business had revenue of $2.68 billion during the quarter, compared to the consensus estimate of $2.67 billion. Iqvia had a return on equity of 15.08% and a net margin of 2.35%. Iqvia’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.34 earnings per share. As a group, equities analysts forecast that Iqvia Holdings Inc will post 5.88 EPS for the current year.
In related news, Director Group Holdings (Sbs) Advis Tpg sold 4,044,480 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $140.80, for a total value of $569,462,784.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ari Bousbib sold 96,000 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $140.96, for a total value of $13,532,160.00. The disclosure for this sale can be found here. Insiders sold 4,214,778 shares of company stock valued at $593,327,768 over the last 90 days. 6.00% of the stock is currently owned by company insiders.
Several research firms have weighed in on IQV. Zacks Investment Research upgraded Iqvia from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. TheStreet cut Iqvia from a “b” rating to a “c+” rating in a research note on Wednesday, May 1st. Wolfe Research began coverage on Iqvia in a research note on Tuesday, April 2nd. They set a “market perform” rating for the company. Barclays upped their target price on Iqvia from $160.00 to $167.00 and gave the stock an “overweight” rating in a research note on Monday, March 18th. Finally, Argus upped their target price on Iqvia from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, February 25th. They noted that the move was a valuation call. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $146.88.
ILLEGAL ACTIVITY NOTICE: “Raymond James & Associates Boosts Stake in Iqvia Holdings Inc (IQV)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2019/05/15/raymond-james-associates-boosts-stake-in-iqvia-holdings-inc-iqv.html.
Iqvia Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Recommended Story: Hedge Funds – Risk or Reward?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.